Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)

SHA:603707 Revenue

Nanjing King-Friend Biochemical Pharmaceutical had revenue of 997.60M CNY in the quarter ending June 30, 2026, a decrease of -8.86%. This brings the company's revenue in the last twelve months to 3.94B, up 4.69% year-over-year. In the year 2025, Nanjing King-Friend Biochemical Pharmaceutical had annual revenue of 3.99B with 1.71% growth. That makes Nanjing King-Friend Biochemical Pharmaceutical the 10,307th largest company in the world by revenue and 1,676th in China.

• Revenue (ttm): 3.94B
• Revenue Growth: +4.69%
• P/S Ratio: 3.34
• Revenue / Employee: 2.53M
• Employees: 1,558
• Market Cap: 13.16B

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	3.99B	67.09M	1.71%
Dec 31, 2024	3.92B	-7.80M	-0.20%
Dec 31, 2023	3.93B	218.67M	5.89%
Dec 31, 2022	3.71B	26.03M	0.71%
Dec 31, 2021	3.69B	771.81M	26.48%

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 13, 2026

Data Sources Report a data error